DEA Warns About Overprescription Of ADHD Medication

Telehealth companies under investigation for excessive advertising on social media platforms

At a glance

  • The Drug Enforcement Administration (DEA) has warned that “aggressive marketing practices” by telehealth companies could be adding to the overprescribing of attention hyperactivity disorder (ADHD) medications.
  • Adderall prescriptions increased by 10.4 percent in 2021 and 10.9 percent through October 2022, compared to an approximately 5 percent increase in the three years prior.
  • A letter from the DEA to drug manufacturers said, “DEA must ensure that any quota granted for the manufacturing of controlled substances used to treat ADHD is driven by a legitimate need and not improperly driven purely by profit motive, pressure from marketing firms, or a desire to obtain more market share—all factors that led to an oversupply of opioids during the prescription opioid crisis.”

Top News Stories

Sponsored